Apellis Pharmaceuticals (APLS) EBIAT (2020 - 2025)
Historic EBIAT for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $215.7 million.
- Apellis Pharmaceuticals' EBIAT rose 47551.57% to $215.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.0 million, marking a year-over-year increase of 11798.71%. This contributed to the annual value of -$197.9 million for FY2024, which is 6256.76% up from last year.
- As of Q3 2025, Apellis Pharmaceuticals' EBIAT stood at $215.7 million, which was up 47551.57% from -$42.2 million recorded in Q2 2025.
- Over the past 5 years, Apellis Pharmaceuticals' EBIAT peaked at $215.7 million during Q3 2025, and registered a low of -$219.2 million during Q2 2021.
- In the last 5 years, Apellis Pharmaceuticals' EBIAT had a median value of -$138.9 million in 2022 and averaged -$107.6 million.
- As far as peak fluctuations go, Apellis Pharmaceuticals' EBIAT tumbled by 28901.55% in 2021, and later skyrocketed by 47551.57% in 2025.
- Quarter analysis of 5 years shows Apellis Pharmaceuticals' EBIAT stood at -$147.9 million in 2021, then dropped by 12.21% to -$166.0 million in 2022, then skyrocketed by 46.64% to -$88.6 million in 2023, then soared by 58.96% to -$36.4 million in 2024, then soared by 693.39% to $215.7 million in 2025.
- Its last three reported values are $215.7 million in Q3 2025, -$42.2 million for Q2 2025, and -$92.2 million during Q1 2025.